Bar Harbor Wealth Management Has $64.85 Million Stock Position in Eli Lilly and Company $LLY

Bar Harbor Wealth Management reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% in the first quarter, HoldingsChannel reports. The fund owned 70,505 shares of the company’s stock after selling 1,605 shares during the period. Eli Lilly and Company accounts for 3.8% of Bar Harbor Wealth Management’s portfolio, making the stock its 4th biggest holding. Bar Harbor Wealth Management’s holdings in Eli Lilly and Company were worth $64,848,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $25,000. Osbon Capital Management LLC bought a new position in Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its position in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares in the last quarter. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company during the fourth quarter valued at $30,000. Finally, 10Elms LLP boosted its holdings in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly completed its acquisition of Centessa Pharmaceuticals, strengthening its sleep-wake disorder pipeline and adding orexin-based drug development assets. Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
• Positive Sentiment: The company announced a potential $1.9 billion research collaboration with Abbisko Therapeutics, expanding its global drug-discovery efforts and pipeline optionality. Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
• Positive Sentiment: Lilly said China approval for its GLP-1 obesity/diabetes pill could come as soon as later in 2026, reinforcing expectations for another major growth driver beyond Mounjaro and Zepbound. China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
• Positive Sentiment: Management also signaled a Europe launch strategy for the obesity pill, suggesting Lilly is preparing to expand its weight-loss franchise internationally as approvals progress. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Eli Lilly and Company Trading Up 0.8%

Shares of NYSE:LLY opened at $1,115.98 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The stock’s fifty day moving average price is $1,026.17 and its 200-day moving average price is $1,018.81. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market cap of $1.05 trillion, a P/E ratio of 39.64, a PEG ratio of 1.21 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the prior year, the business earned $3.34 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analyst Ratings Changes

A number of research firms have recently commented on LLY. Berenberg Bank increased their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday. Barclays lifted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Finally, Bank of America increased their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,230.89.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.